Looking to publish in JTO Clinical and Research Reports? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowJTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It complements the Journal of Thoracic Oncology by offering a gold open access publication option and particularly publishes Phase I trials, well performed single-arm phase II trials, subset analyses of published trials, impactful retrospective studies, database analysis, large institutional series, high-quality case reports, region-specific clinical trials, subspecialty thoracic oncology studies, and selected high-quality meeting reports.
Looking to publish in JTO Clinical and Research Reports? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
JTO Clinical and Research Reports accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Review Articles
Brief Reports
Case Reports
Letters To The Editor
Recent Publications
Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC – primary analysis of the ATORG-003 phase 2 trial
Aaron C. Tan, Tae Min Kim, Siqin Zhou, Yueh Ni Lim, Gwo Fuang Ho, Lye Mun Tho, Thanyanan Baisamut, Naiyarat Prasongsook, Suee Lee, Sze Huey Tan, Dong-Wan Kim, Tony Mok, Daniel S.W. Tan, Herbert H. Loong
Prophylactic Cranial Irradiation and Survival in Limited-Stage Small Cell Lung Cancer: A Multicenter Real-World Analysis from the Canadian Small Cell Lung Cancer Database (CASCADE)
Abdul Hadee Lone, Xiang Y. Ye, Luna Jia Zhan, Haechan Yang, Victoria Smyth, Riham H. Abdelaziz, Stephanie Snow, Sofia Genta, Sara Kuruvilla, Jason Agulnik, Vishal Navani, Cheryl Ho, David Dawe, Paul Wheatley-Price, Sara Moore, Geoffrey Liu, Benjamin H. Lok
Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda, Makiko Yamaguchi, Tamotsu Ishizuka, Satoko Baba, Kengo Takeuchi, Shinji Takeuchi
Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1
Marina Chiara Garassino, Ana Baramidze, Saadettin Kilickap, Ahmet Sezer, Mustafa Özgüroğlu, Mahmut Gumus, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Gwo Fuang Ho, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Xue Jia, Debra A.G. McIntyre, Stefanie Chua, Manika Kaul, Javier Perez, Israel Lowy, Frank Seebach, Eric Kim, Heather Magnan, Jean-Francois Pouliot
RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC
Pedro de Marchi, Yun Fan, Zhiyong Ma, Yan Wang, Yuanyuan Bao, Wenjuan Zheng, Kirsha Naicker, Caicun Zhou
Frequently asked questions
How long does it take to publish?
9 days submission to first decision; 47 days submission to decision after review; 111 days submission to acceptance; 6 days acceptance to online publication.
Reformat to JTO Clinical and Research Reports using Livewrite PremiumWhat are the publication costs?
Article Publishing Charge (APC): USD 2,000 (excluding taxes).
Reformat to JTO Clinical and Research Reports using Livewrite Premium